- All sections
- C - Chemistrymetallurgy
- C12N - Microorganisms or enzymescompositions thereofpropagating, preserving, or maintaining microorganismsmutation or genetic engineeringculture media
- C12N 9/68 - Plasmin, i.e. fibrinolysin
Patent holdings for IPC class C12N 9/68
Total number of patents in this class: 82
10-year publication summary
|
4
|
8
|
6
|
5
|
4
|
8
|
6
|
6
|
3
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1260 |
9 |
| Previpharma Consulting GmbH | 17 |
7 |
| Monash University | 704 |
5 |
| Gentium S.r.l. | 35 |
4 |
| Kedrion Biopharma Inc. | 16 |
4 |
| ThromboGenics NV | 13 |
4 |
| ProMetic BioTherapeutics, Inc. | 12 |
4 |
| Kedrion S.p.A. | 50 |
3 |
| Talecris Biotherapeutics, Inc. | 13 |
3 |
| Bioatla, Inc. | 106 |
3 |
| Immunofyx | 3 |
3 |
| Bausch & Lomb Incorporated | 1125 |
2 |
| CSL Behring AG | 170 |
2 |
| Grifols Therapeutics Inc. | 17 |
2 |
| Talengen International Limited | 79 |
2 |
| E. I. du Pont de Nemours and Company | 4118 |
1 |
| Massachusetts Institute of Technology | 10013 |
1 |
| Korea Institute of Science and Technology | 2114 |
1 |
| AB Enzymes Oy | 73 |
1 |
| Anhui New Star Pharmaceutical Development Co., Ltd. | 13 |
1 |
| Other owners | 20 |